Evidence map›Paper›PMID 26579216›Full record

ArticleMolecular autism2015

Cytoplasm-predominant Pten associates with increased region-specific brain tyrosine hydroxylase and dopamine D2 receptors in mouse model with autistic traits.

Xin He, Stetson Thacker, Todd Romigh, Qi Yu, Thomas W Frazier, Charis Eng

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular autism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Autism Spectrum Disorder Associated with Germline HeterozygousCold Spring Harbor perspectives in medicine · 2019
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xin HeGenomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50, Cleveland, OH 44195 USA ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA.
Stetson ThackerGenomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50, Cleveland, OH 44195 USA ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA ; HHMI Graduate Program, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH USA.
Todd RomighGenomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50, Cleveland, OH 44195 USA ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA.
Qi YuGenomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50, Cleveland, OH 44195 USA ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA.
Thomas W FrazierGenomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50, Cleveland, OH 44195 USA ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA ; HHMI Graduate Program, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH USA ; Center for Autism, Pediatrics Institute, Cleveland Clinic, Cleveland, OH USA ; Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH USA.
Charis EngGenomic Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Mailstop NE-50, Cleveland, OH 44195 USA ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA ; HHMI Graduate Program, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH USA ; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH USA ; Stanley Shalom Zielony Institute of Nursing Excellence, Cleveland Clinic, Cleveland, OH USA ; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH USA ; CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA.
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · USCase Western Reserve University · US

Funding

Toward better characterization and clinical trial readiness for targeting neuropsychiatric manifestations in PTEN pathogenic variantsU54NS092090 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI M. Pilar Trelles · 2014 to 2026
$20.1M
NINDS NIH HHS U54 NS092090
6 · The paper itself

Abstract

backgroundAutism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by impairment in social communication/interaction and inflexible/repetitive behavior. Several lines of evidence support genetic factors as a predominant cause of ASD. Among those autism susceptibility genes that have been identified, the PTEN tumor suppressor gene, initially identified as predisposing to Cowden heritable cancer syndrome, was found to be mutated in a subset of ASD patients with extreme macrocephaly. However, the ASD-relevant molecular mechanism mediating the effect of PTEN mutations remains elusive.

methodsWe developed a Pten knock-in murine model to study the effects of Pten germline mutations, specifically altering subcellular localization, in ASD. Proteins were isolated from the hemispheres of the male littermates, and Western blots were performed to determine protein expression levels of tyrosine hydroxylase (TH). Immunohistochemical stains were carried out to validate the localization of TH and dopamine D2 receptors (D2R). PC12 cells ectopically expressing either wild-type or missense mutant PTEN were then compared for the differences in TH expression.

resultsMice carrying Pten mutations have high TH and D2R in the striatum and prefrontal cortex. They also have increased phosphorylation of cAMP response element-binding protein (CREB) and TH. Mechanistically, PTEN downregulates TH production in PC12 cells via inhibiting the phosphoinositide 3-kinase (PI3K)/CREB signaling pathway, while PTEN reduces TH phosphorylation via suppressing MAPK pathway. Unlike wild-type PTEN but similar to the mouse knock-in mutant Pten, three naturally occurring missense mutations of PTEN that we previously identified in ASD patients, H93R, F241S, and D252G, were not able to suppress TH when overexpressed in PC12 cells. In addition, two other PTEN missense mutations, C124S (pan phosphatase dead) and G129E (lipid phosphatase dead), failed to suppress TH when ectopically expressed in PC12 cells.

conclusionsOur data reveal a non-canonical PTEN-TH pathway in the brain that may work as a core regulator of dopamine signaling, which when dysfunctional is pathogenic in ASD.

Indexed as

AutismDopamineGenePTENTyrosine hydroxylase

Identifiers

PMID26579216
PMCPMC4647625
OpenAlexW2174293521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.